{"filings":[{"id":2078685,"accession_number":"0001759425-26-000044","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2026-08-05T20:02:41+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mirum Q2 net product sales $176M, raises FY guidance to $680-700M; volixibat NDA delayed to H1 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2026 net product sales $176.2M, up 38% YoY; LIVMARLI sales $128.7M (+46% YoY), Bile Acid Medicines $47.5M (+20% YoY).","Full-year 2026 net product sales guidance raised to $680-700M from prior range.","Volixibat granted Breakthrough Therapy and Orphan Drug Designations for PSC; pre-NDA meeting recommended Phase 3 study, NDA submission now targeted H1 2027.","Issued $690M of 0.00% convertible senior notes due 2032; settled $237.2M of 4.00% notes due 2029.","Cash and investments $561.3M as of June 30, 2026; zilurgisertib PDUFA date Sept 26, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1138324,"accession_number":"0001193125-26-275811","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2026-06-18T20:05:38+00:00","items":["5.07"],"status":"ready","headline":"Mirum Pharma annual meeting: all director nominees elected, auditor ratified, say-on-pay approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders elected Lon Cardon, William Fairey, and Timothy Walbert as Class I directors with 39.6M, 40.3M, and 32.3M votes for, respectively.","Ratification of Ernst & Young as independent auditor for FY 2026 passed with 49.99M votes for, 5,674 against.","Advisory vote on executive compensation approved with 44.5M votes for, 1.87M against, and 3.6M broker non-votes.","As of record date April 20, 2026, 60,977,841 shares were outstanding and entitled to vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":499038,"accession_number":"0001193125-26-228902","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2026-05-18T20:06:05+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Mirum issues $690M zero-coupon convertible notes due 2032; exchanges $237M of 2029 notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $690M aggregate principal of 0.00% Convertible Senior Notes due 2032, including $90M option exercise.","Initial conversion price ~$138.94 per share, a 30% premium over $106.88 closing price on pricing date.","Concurrently exchanged ~$237.2M of existing 4.00% 2029 notes for $475M cash and ~3.22M shares.","Net proceeds ~$671.6M; remainder for general corporate purposes and potential acquisitions.","Notes mature June 1, 2032; redeemable after June 6, 2029 under stock price conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95254,"accession_number":"0001759425-26-000036","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mirum Q1 net sales $159.9M, raises FY guidance to $660-680M; volixibat & brelovitug meet primary endpoints","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2026 net product sales $159.9M, up 43% YoY; LIVMARLI $113.8M (+55%), Bile Acid Medicines $46.1M (+20%).","Full-year 2026 net product sales guidance raised to $660-680M from prior range.","Volixibat VISTAS Phase 2b in PSC met primary endpoint; NDA submission expected H2 2026.","Brelovitug AZURE-1 Phase 2b in HDV met primary endpoint; Phase 3 enrollment complete, topline H2 2026.","In-licensed zilurgisertib for FOP from Incyte for $16M upfront; FDA Priority Review, PDUFA Sept 26, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-13.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":159882000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95253,"accession_number":"0001193125-26-202609","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Mirum's volixibat meets primary endpoint in PSC Phase 2b VISTAS study with statistically significant itch reduction","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Volixibat showed 2.72 point improvement in pruritus vs 1.08 for placebo; placebo-adjusted difference 1.64 (p<0.0001).","55.6% of volixibat patients achieved ≥2 point reduction in Adult ItchRO vs 26.3% for placebo (p=0.0019).","Pre-NDA meeting with FDA scheduled summer 2026; NDA submission planned H2 2026.","VANTAGE Phase 2b study in PBC top-line data now expected Q1 2027.","Most common adverse event was diarrhea (40.3% volixibat vs 8.6% placebo); SAEs in volixibat group not considered related."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95252,"accession_number":"0001193125-26-179048","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2026-04-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Mirum's brelovitug meets Phase 2b primary endpoint in chronic HDV; 100% virologic response at 300 mg QW","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["100% of patients on 300 mg QW and 75% on 900 mg Q4W achieved virologic response vs 0% control.","Primary composite endpoint (virologic response + ALT normalization) reached by 45% and 35% vs 0% control (p=0.003, 0.024).","Brelovitug was well tolerated; no discontinuations, low grade 3+ events, no related serious AEs.","Full Phase 2b results to be presented at EASL Congress May 27-30, 2026.","Phase 3 topline data from AZURE-1/4 expected H2 2026; potential U.S. BLA submission in 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95251,"accession_number":"0001759425-26-000021","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K/A","filed_at":"2026-04-08T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Mirum completes acquisition of Bluejay Therapeutics with $268.5M PIPE; Bluejay reports 2025 net loss of $101.7M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Concurrent PIPE raised $268.5M gross at $68.48/sh including pre-funded warrants.","Bluejay 2025 audited: net loss $101.7M, R&D $87.1M, total assets $85.6M, accumulated deficit $190M.","Bluejay had substantial doubt about going concern; Mirum committed to fund operations post-close.","Lead candidate brelovitug (BJT-778) for chronic hepatitis delta is in clinical development.","Pro forma financials for combined entity filed; acquisition closed Jan 23, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108171,"accession_number":"0001759425-26-000010","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mirum Pharma 2025 sales $521M (+55% YoY); guides 2026 $630-650M; multiple pipeline readouts in 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["2025 net product sales $521.3M, up from $336.4M in 2024 (+55% YoY). LIVMARLI US sales $244.7M (+69% YoY).","2026 guidance: global net product sales $630-650M, reflecting continued growth.","Pipeline catalysts: Volixibat VISTAS (PSC) topline Q2 2026; Livmarli EXPAND data Q4 2026; Brelovitug HDV data H2 2026.","Completed acquisition of Bluejay Therapeutics for brelovitug; raised $268.5M in private placements.","Cash and investments $391.4M as of Dec 31, 2025; operating expenses $543.4M (incl. $95M non-cash)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":521312000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108170,"accession_number":"0001193125-26-022582","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2026-01-26T23:59:59+00:00","items":["2.01","7.01","8.01","9.01"],"status":"ready","headline":"Mirum acquires Bluejay for $280.8M cash + stock; adds late-stage HDV therapy","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront consideration $280.8M cash plus ~4.67M shares; holdback $25.8M plus ~0.52M shares; up to $200M milestones.","Added brelovitug (anti-HDV mAb) with FDA Breakthrough Therapy and EMA PRIME; Phase 3 AZURE topline data expected 2H 2026.","Concurrent private placements raised ~$268.5M gross proceeds to support brelovitug development and commercial activities.","Mirum also acquired Bluejay's net cash of ~$56.6M.","Entities affiliated with Frazier Life Sciences (board member >5% holder) received pro rata portion of consideration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108169,"accession_number":"0001759425-26-000004","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Mirum prelim 2025 sales ~$520M, above guidance; 2026 outlook $630-650M; acquiring Bluejay for HDV","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary 2025 net product sales ~$520M, exceeding upper end of guidance.","2026 guidance: global net sales $630M-$650M; positive cash flow from operations in 2025.","LIVMARLI 2025 sales ~$359M (US $243M, +69% YoY); CHOLBAM/CTEXLI ~$161M (+31% YoY).","Proposed acquisition of Bluejay Therapeutics (brelovitug for HDV) expected close late Jan 2026; $268.5M private placements.","Pipeline: volixibat PSC topline Q2 2026; LIVMARLI EXPAND topline Q4 2026; HDV AZURE data H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":521312000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124599,"accession_number":"0001193125-25-326822","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Mirum Pharmaceuticals sues Sandoz, Annora, Zydus, Zenara over generic Livmarli ANDAs","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Received Paragraph IV notice letters from Sandoz, Annora Pharma, Zydus Lifesciences, and Zenara Pharma seeking generic Livmarli.","Filed patent infringement suits on December 19, 2025 in U.S. District Court for Delaware.","Suits assert infringement of Orange Book patents for LIVMARLI (maralixibat).","Suits seek FDA approval no earlier than expiration of last asserted patent.","30-month stay prevents FDA from granting final approval of the ANDAs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124598,"accession_number":"0001193125-25-325825","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Mirum Pharmaceuticals secures additional $68.5M PIPE from TCGX ahead of Bluejay acquisition","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["1,000,000 shares at $68.48/share; ~$68.5M gross proceeds from TCGX.","Combined with Dec 2025 $200M PIPE raises total ~$268.5M to fund Bluejay acquisition.","Both PIPE and Bluejay acquisition expected to close in Q1 2026, subject to conditions.","Registration rights agreement provides for resale registration of the PIPE shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124597,"accession_number":"0001193125-25-310611","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Mirum Pharmaceuticals to Acquire Bluejay Therapeutics for Up to $820M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Mirum pays $250M cash and up to 5.2M shares (≈$370M) at closing, plus up to $200M in milestone payments for Bluejay Therapeutics.","Acquisition adds brelovitug, a Phase 3 monoclonal antibody for chronic hepatitis D (HDV) with Breakthrough Therapy and PRIME designations.","Mirum also raised $200M in a PIPE from investors including Morgan Stanley, Leerink, Cantor, Raymond James, and Citizens JMP.","Top-line Phase 3 data for brelovitug expected in second half of 2026; BLA submission anticipated in first half of 2027.","Transaction expected to close in Q1 2026, subject to HSR clearance, stockholder approval, and other customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124596,"accession_number":"0001759425-25-000057","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Mirum receives Sandoz Paragraph IV notice challenging Livmarli patents; plans to sue","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Sandoz filed ANDA seeking FDA approval for generic Livmarli (maralixibat).","Sandoz alleges five Livmarli Orange Book patents are invalid or not infringed.","Mirum has 45 days to sue, triggering a 30-month FDA approval stay.","Mirum expects additional Paragraph IV notices from other ANDA filers.","Company vows to vigorously enforce IP and seek a permanent injunction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124595,"accession_number":"0001759425-25-000053","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mirum Q3 revenue $133M, up 47% YoY; lifts FY guidance to $500-510M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2025 total revenue $133.0M vs $90.4M in Q3 2024; LIVMARLI sales $92.2M (+56% YoY).","Bile Acid Medicines net sales $40.8M, up 31% YoY; cash and investments $378M.","Volixibat VISTAS (PSC) enrollment complete; topline data expected Q2 2026.","Volixibat VANTAGE (PBC) and LIVMARLI EXPAND enrollment expected 2026; topline H1 2027.","Phase 2 study of MRM-3379 for Fragile X Syndrome initiated."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":372380000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141266,"accession_number":"0001759425-25-000040","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mirum Q2 revenue $127.8M; raises FY 2025 guidance to $490-510M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 global net product sales $127.8M, up 64% YoY from $77.9M.","LIVMARLI sales $88.2M (+87% YoY); Bile Acid Medicines $39.6M (+30%).","FY 2025 revenue guidance raised to $490-510M from prior range.","Cash $321.7M; volixibat VISTAS topline expected Q2 2026.","MRM-3379 Phase 2 in Fragile X expected Q4 2025 initiation."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":239370000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159077,"accession_number":"0001759425-25-000034","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Mirum Pharmaceuticals 2025 Annual Meeting results: three directors elected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class III directors elected: Laura Brege (17.97M for, 18.17M withheld), Michael Grey (30.78M for), Christopher Peetz (35.98M for).","Ratified Ernst & Young as independent auditor for FY2025: 43.12M for, 19.2K against, 19.4K abstentions.","Advisory vote on executive compensation approved: 34.67M for, 1.46M against, 8.9K abstentions.","Broker non-votes of 7.02M on director elections and compensation proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159076,"accession_number":"0001759425-25-000030","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mirum Q1 revenue $111.6M; raises 2025 guidance to $435-450M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2025 total revenue $111.6M vs $69.2M YoY, driven by LIVMARLI ($73.2M, +71%) and Bile Acid Medicines ($38.4M, +47%).","Raises full-year 2025 revenue guidance to $435-450M from prior range.","LIVMARLI oral tablet formulation approved by FDA; also approved in Japan for ALGS and PFIC.","VISTAS PSC study enrollment completion expected Q3 2025; topline data Q2 2026.","Cash and investments $298.6M as of March 31, 2025, up from $292.8M at year-end 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":111585000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177524,"accession_number":"0001759425-25-000012","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mirum reports 2024 net product sales $336.4M; guides 2025 sales $420M-$435M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["2024 net product sales $336.4M, up from $178.9M in 2023; LIVMARLI sales $213.3M, Bile Acid Medicines $123.1M.","2025 global net product sales guidance of $420M to $435M; expects positive cash flow.","Volixibat VISTAS PSC study expected to complete enrollment H2 2025; topline data in 2026.","Cash, equivalents and investments $292.8M as of Dec 31, 2024 (vs $286.3M end 2023).","CTEXLI (chenodiol) approved in US for cerebrotendinous xanthomatosis; MRM-3379 Phase 2 in FXS expected in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":336888000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177523,"accession_number":"0001759425-25-000003","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Mirum Pharma 2024 net sales ~$336M, above guidance; 2025 outlook $420-435M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary unaudited FY2024 net product sales ~$336M, exceeding upper end of guidance range.","LIVMARLI net sales ~$213M; CHOLBAM/CHENODAL ~$123M; Q4 2024 sales ~$99M.","2025 guidance: global net product sales $420-435M with positive cash flow from operations.","Year-end cash and investments ~$287M; achieved positive cash from operations in Q3 2024.","Pipeline: PDUFA date for chenodiol in CTX March 28, 2025; volixibat VISTAS enrollment completion H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":336888000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194242,"accession_number":"0001759425-24-000037","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mirum Q3 net product sales $90.3M (+89% YoY); raises FY 2024 guidance to $330-335M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["LIVMARLI net sales $59.1M; CHOLBAM/CHENODAL combined $31.2M.","Cash & investments $293.8M vs $286.3M at Dec 2023; OpEx $103.1M incl $18M non-cash.","PDUFA date for chenodiol in CTX set for Dec 28, 2024.","Volixibat granted breakthrough therapy designation for PBC; interim data at AASLD.","In-licensed PDE4D inhibitor MRM-3379 for Fragile X syndrome; Phase 2 expected in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":237474000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210569,"accession_number":"0001759425-24-000029","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mirum Q2 net product sales $77.8M (+139% YoY); LIVMARLI sales $47.2M; positive volixibat interim data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 global net product sales $77.8M, up 139% vs Q2 2023; full-year guidance reaffirmed at $310-320M.","LIVMARLI net sales $47.2M (+45% YoY); combined CHOLBAM/CHENODAL sales $30.5M.","Positive interim results for volixibat in VISTAS PSC and VANTAGE PBC studies.","LIVMARLI approved in Europe for PFIC (≥3 months) and US label expanded to ≥12 months; NDA filed for chenodiol in CTX.","Cash & investments $295.4M (Dec 2023: $286.3M); operating expenses $102.1M vs $61.8M YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":147097000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228896,"accession_number":"0001193125-24-162056","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Mirum reports positive interim Ph2b data for volixibat in PBC and PSC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["VANTAGE PBC trial: volixibat achieved placebo-adjusted -2.32 point itch reduction (p=0.0026); 75% of patients had >50% drop in serum bile acids.","Significant fatigue improvement at week 16; no new safety signals; diarrhea (77%) mostly mild/moderate and transient; 4 SAEs (1 placebo).","VANTAGE and VISTAS PSC trials to continue with volixibat 20 mg twice daily; independent data review committee recommended continuation for PSC.","No clinically meaningful changes in liver biomarkers in PBC; sponsor remains blinded to interim results."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228895,"accession_number":"0001759425-24-000023","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Stockholders elect all three Class II directors, ratify auditor, approve say-on-pay, set frequency to one year","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Laurent Fischer, Patrick Heron, and Saira Ramasastry as Class II directors (each received >19M votes for).","Ratified Ernst & Young as independent auditor for FY2024 (37.5M for, 36k against, 143k abstain).","Advisory approval of executive compensation: 32.7M for, 1.1M against, 90k abstain.","Advisory vote on say-on-pay frequency: 33.8M for one year; board adopts annual frequency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228894,"accession_number":"0001193125-24-151965","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2024-05-31T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Mirum's LIVMARLI gets positive CHMP opinion for PFIC; EC decision in Q3 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CHMP adopted positive opinion for LIVMARLI (maralixibat) to treat PFIC in patients aged 3 months and older.","CHMP concluded LIVMARLI provides significant clinical benefit vs already-approved PFIC treatment.","COMP recommended maintaining Orphan Drug Designation for LIVMARLI in PFIC.","European Commission decision on marketing authorization expected in Q3 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228893,"accession_number":"0001759425-24-000017","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mirum Q1 revenue $69.2M, up 119% YoY; reaffirms FY guidance $310-320M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Global product sales net $68.9M, up 137% vs Q1 2023; LIVMARLI net sales $42.8M (+47%).","FDA approved LIVMARLI for PFIC cholestatic pruritus in March 2024.","Volixibat interim analyses (VISTAS/VANTAGE) expected June 2024; CHENODAL NDA for CTX on track H1 2024.","Cash and equivalents $302.8M as of March 31, 2024, up from $286.3M at year-end 2023.","Operating expenses $95.7M (incl. $17.1M non-cash items) vs $58.7M in prior-year quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":69222000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247532,"accession_number":"0001759425-24-000005","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mirum reports 2023 net product sales of $178.9M (+142% YoY); guides 2024 sales $310-320M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2023 total revenue $186.4M, up 142% over 2022; LIVMARLI net sales $141.8M (+89% YoY).","2024 global net product sales guidance of $310M to $320M, reflecting continued growth across approved medicines.","LIVMARLI PFIC PDUFA date on track for March 13, 2024; CHENODAL NDA for CTX planned H1 2024.","Volixibat VISTAS (PSC) and VANTAGE (PBC) interim analyses expected in first half 2024.","Appointed Joanne Quan, M.D. as Chief Medical Officer; cash and equivalents $286.3M as of Dec 31, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":186374000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247531,"accession_number":"0001193125-24-008569","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2024-01-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Mirum Pharmaceuticals promotes Peter Radovich to President effective Jan 16, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Peter Radovich promoted to President, effective Jan 16, 2024, while continuing as COO.","Christopher Peetz remains CEO; Radovich had served as COO since April 2020.","Radovich previously held senior roles at Global Blood Therapeutics and Onyx Pharmaceuticals.","Promotion expands Radovich's responsibilities but no change in CEO role."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247530,"accession_number":"0001193125-24-003965","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Mirum announces preliminary 2023 net product sales of $178-180M; LIVMARLI sales up 89% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary 2023 total revenue $186-188M; net product sales $178-180M.","LIVMARLI net product sales $141-143M, ~89% YoY growth.","Q4 2023 net product sales $69-71M (LIVMARLI $41-43M; CHOLBAM & CHENODAL ~$28M).","FDA PDUFA for LIVMARLI in PFIC on March 13, 2024; NDA submission for CHENODAL in CTX in H1 2024.","Appointed Eric Bjerkholt as CFO; company fully financed with strong balance sheet."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":186374000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264998,"accession_number":"0001193125-23-297614","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2023-12-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Mirum's LIVMARLI fails Phase 2b EMBARK trial in biliary atresia; primary endpoint not met","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2b EMBARK trial of LIVMARLI (maralixibat) in biliary atresia did not meet primary or key secondary endpoints.","LIVMARLI was generally well-tolerated with no new safety findings.","Topline results announced on December 18, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264997,"accession_number":"0001157523-23-001631","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mirum Q3 revenue $47.7M, LIVMARLI sales up 106%; CHENODAL/CHOLBAM acquisition completed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2023 total revenue $47.7M (up 154% YoY); LIVMARLI global net sales $38.7M, +106% vs Q3 2022.","Acquisition of CHENODAL and CHOLBAM closed Aug 31; contributed $9M in Q3 sales.","Positive Phase 3 RESTORE for CHENODAL in CTX; NDA filing expected H1 2024; sNDA for LIVMARLI in PFIC PDUFA March 13, 2024.","Cash and investments $306M; convertible debt $316.3M; pipeline catalysts: EMBARK data by year-end, volixibat data H1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":116820000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264994,"accession_number":"0001193125-23-269359","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K/A","filed_at":"2023-11-02T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Mirum acquires Bile Acid Business from Travere for up to $445M; H1 2023 revenue $53.6M, net income $13.6M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired Chenodal and Cholbam assets for up to $445M ($210M upfront + up to $235M milestone payments).","PIPE of 8M shares at $26.25 raised ~$202.2M net proceeds to fund acquisition.","Acquired business had net product sales of $53.6M and net income of $13.6M for H1 2023 (unaudited).","Pro forma combined financial statements filed; acquisition closed August 31, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264996,"accession_number":"0001193125-23-257711","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2023-10-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA extends review of Mirum's LIVMARLI sNDA for PFIC; new PDUFA date March 13, 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA extended PDUFA goal date to March 13, 2024, from original October 2023 target.","Extension due to FDA deeming Company's response to information request a major amendment.","Submission included further analysis of previously provided clinical data; no new data or studies requested.","LIVMARLI is under review for treatment of cholestatic pruritus in PFIC patients.","Company notes no additional FDA information requests beyond the major amendment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264995,"accession_number":"0001193125-23-256103","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2023-10-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Mirum files updated risk factor disclosure; no financial or operational news","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Update includes risks related to sole-source contract manufacturers for commercial supplies.","Lists risk of needing additional financing for commercialization and product development.","Notes potential delays in patient enrollment and clinical trial completion.","References the Asset Purchase and risk of not realizing its anticipated benefits."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282179,"accession_number":"0001193125-23-232481","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2023-09-11T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Mirum appoints Eric Bjerkholt as CFO effective Sept 11, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eric Bjerkholt appointed CFO; previously CFO at Chinook Therapeutics and Aimmune Therapeutics.","Base salary of $485,000 and annual bonus target of 40% of base salary.","Granted option for 110,000 shares and RSU for 55,000 shares, both with four-year vesting.","Severance: 9-month salary and 12-month equity acceleration outside CIC; 18-month salary +150% bonus + full acceleration within CIC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282178,"accession_number":"0001193125-23-228131","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2023-09-05T23:59:59+00:00","items":["2.01","3.02","7.01","9.01"],"status":"ready","headline":"Mirum acquires Travere's bile acid products Cholbam and Chenodal for $210M upfront plus $235M milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Completed asset purchase of Cholbam and Chenodal from Travere for $210M cash at closing, with up to $235M in sales-based milestone payments.","Funded acquisition via $210M PIPE at $26.25/share from investors including Frazier Life Sciences, Avidity Partners, BVF Partners.","Products treat rare liver diseases: bile acid synthesis disorders, peroxisomal disorders; Chenodal in Phase 3 for cerebrotendinous xanthomatosis (CTX).","Travere received $210M upfront and is eligible for additional milestones; Mirum expects near-term label expansion opportunity for CTX.","Financial statements for the acquired business to be filed as an amendment to this 8-K within 71 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282177,"accession_number":"0001193125-23-224944","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2023-08-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Mirum amends severance plan; expands CEO/NEO change-in-control benefits","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Peetz: 12mo base salary + 12mo equity vesting (non-CIC); 24mo salary + 200% bonus + full vesting (CIC).","NEOs Longpre, Radovich, Vig: 9mo salary + 12mo vesting (non-CIC); 18mo salary + 150% bonus + full vesting (CIC).","Plan amendment removes automatic sunset provision; administrative changes made.","New participation agreements with each NEO reflect modified benefits."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282176,"accession_number":"0001157523-23-001254","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mirum reports Q2 revenue $37.5M, LIVMARLI sales $32.5M; acquires CHENODAL/CHOLBAM for $210M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Q2 total revenue $37.5M (incl $5M license); LIVMARLI net sales $32.5M, up 86% YoY.","Acquiring CHENODAL and CHOLBAM from Travere for $210M upfront + up to $235M milestones.","Entered $210M private placement to fund acquisition; closed $316.3M convertible notes at 4% due 2029.","Pipeline readouts H2 2023: EMBARK (biliary atresia), volixibat PSC/PBC, CHENODAL RESTORE.","Cash $330M as of June 30; repurchased 9.75% royalty obligation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282175,"accession_number":"0001193125-23-187712","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2023-07-17T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Mirum to acquire Travere's bile acid portfolio for up to $445M; raises $210M PIPE to fund","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquires Cholbam and Chenodal for $210M upfront plus up to $235M in sales-based milestones tiered from $125M to $500M in annual net sales.","Raises ~$210M via PIPE at $26.25/share (July 14 close) from Frazier Life Sciences, Avidity, BVF, Longitude, Sofinnova, and others.","Deal expected to close Q3 2023, subject to HSR clearance and customary conditions; Travere to provide transitional services.","Mirum to leverage rare liver disease expertise for Cholbam/Chenodal; also sponsors genetic testing program.","Travere divests to focus on FILSPARI launch, sparsentan in FSGS, and pegtibatinase; proceeds extend cash runway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301311,"accession_number":"0001193125-23-166018","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2023-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Mirum Pharmaceuticals announces results of 2023 annual meeting of stockholders","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Lon Cardon, William Fairey, and Timothy Walbert as Class I directors to serve until 2026.","Each director received overwhelming support: Cardon 30.6M for, Fairey 30.4M for, Walbert 27.5M for.","Ratified Ernst & Young as independent auditor for FY 2023 with 34.2M votes for, 3.4K against.","Total shares outstanding and entitled to vote: 38,030,661 as of record date April 17, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301310,"accession_number":"0001157523-23-000741","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mirum Q1 2023 LIVMARLI sales $29.1M, up 167% YoY; closed $316M convertible note","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales for LIVMARLI $29.1M in Q1 2023 vs $10.9M in Q1 2022, a 167% increase.","Total revenue $31.6M; operating expenses $58.7M; cash $232.1M as of March 31, 2023.","FDA approved label expansion for LIVMARLI to include infants 3 months+ in Alagille syndrome.","sNDA for LIVMARLI in PFIC accepted with PDUFA date December 13, 2023.","Closed $316.3M upsized convertible notes offering at 4.00% due 2029; repurchased 9.75% royalty obligation."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":31598000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301309,"accession_number":"0001193125-23-103622","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2023-04-17T23:59:59+00:00","items":["1.01","1.02","2.03","3.02","9.01"],"status":"ready","headline":"Mirum prices $316.25M 4.00% convertible notes due 2029; repurchases $192.7M revenue interests","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $316.25M principal (incl. full exercise of $41.25M over-allotment) of 4.00% convertible senior notes due May 1, 2029.","Initial conversion price ~$31.74/share, a 35% premium over $23.51 closing stock price on April 12, 2023.","Net proceeds ~$305.4M; used ~$192.7M to repurchase revenue interests from Oberland Capital (RIPA) and terminate that agreement.","Remaining proceeds expected for general corporate purposes, including working capital and potential acquisitions.","Notes are senior unsecured; callable by Mirum after May 5, 2026 if stock price >130% of conversion price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301308,"accession_number":"0001193125-23-098423","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2023-04-12T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Mirum reports preliminary Q1 2023 revenue of $31.5M, cash $232.1M; updates VISTAS trial timeline","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q1 2023 total revenue ~$31.5M, product sales net ~$29M, license revenue ~$2.5M.","Cash, cash equivalents and short-term investments ~$232.1M as of March 31, 2023.","Operating expenses consistent to moderately increased versus Q4 2022.","VISTAS Phase 2b (volixibat in PSC) blinded interim analysis now expected H2 2023.","VANTAGE Phase 2b (PBC) interim and EMBARK Phase 2b (biliary atresia) topline data remain on track for H2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":31598000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301307,"accession_number":"0001193125-23-093126","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2023-04-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Mirum appoints Timothy Walbert to Board; Niall O'Donnell to resign at 2023 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Timothy Walbert appointed to Board as Class I director effective April 5, 2023.","Walbert receives option for 34,000 shares vesting over 3 years and $45,000 annual cash retainer.","Niall O'Donnell resigns as director and from Nominating and Corporate Governance Committee, effective at 2023 annual meeting, no dispute.","Walbert will serve until 2023 annual meeting and then be eligible for annual option grant of 17,000 shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321150,"accession_number":"0001193125-23-067794","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2023-03-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Mirum reports immaterial SVB exposure (<1% of cash)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Less than 1% of cash, equivalents, restricted cash and investments held at SVB.","SVB placed under FDIC receivership; company believes exposure is immaterial.","May experience delays in transferring funds due to banking system disruption.","No other financial impact disclosed as of March 10, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321149,"accession_number":"0001157523-23-000411","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2023-03-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mirum reports FY 2022 LIVMARLI net product sales of $75.1M; Q4 sales up 48% QoQ","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2022 LIVMARLI net product sales $75.1M (vs $3.1M in 2021); total revenue $77.1M.","Q4 2022 net sales up 48% vs Q3 2022; U.S. business guided for 50% growth in 2023.","Operating expenses $208.3M for 2022 (up from $192.6M in 2021); cash & investments $251.7M.","sNDA submitted for LIVMARLI in PFIC; data milestones in biliary atresia (H2 2023) and volixibat programs.","Capital raises net $121.9M since Jan 2022; net royalty obligations reduced via Satiogen acquisition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321148,"accession_number":"0001193125-23-004231","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Mirum reports $76M total rev in 2022; LIVMARLI net sales $74M; CFO Clements to step down","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $76M, LIVMARLI net product sales $74M for full year 2022 (preliminary unaudited).","Q4 2022 product sales $27M including $5M international partner orders.","CFO Ian Clements to step down effective May 15, 2023; will serve as consultant for 12 months.","sNDA for LIVMARLI in PFIC on track for Q1 2023; multiple pipeline catalysts in 2023.","Cash and investments ~$252M as of Dec 31, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":77062000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339255,"accession_number":"0001193125-22-307926","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2022-12-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Mirum Pharmaceuticals director Carol Brosgart resigns, becomes senior advisor; Lon Cardon appointed to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Carol L. Brosgart resigned as director and Nominating Committee member effective Dec 19, 2022; no dispute; becomes senior advisor in science and policy.","Lon Cardon, Ph.D., appointed to board as Class I director, term expiring at 2023 annual meeting, and to Nominating and Corporate Governance Committee.","Cardon receives option for 34,000 shares vesting in 3 equal annual installments, plus annual cash retainer of $40,000 ($4,000 for committee service) prorated for 2022.","Cardon eligible for annual option grant of 17,000 shares starting at 2023 annual meeting, prorated per policy.","Standard indemnification agreement entered; no arrangements with other persons for selection."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339254,"accession_number":"0001193125-22-303831","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2022-12-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Mirum receives EC approval for LIVMARLI in Alagille syndrome across EU","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["European Commission granted marketing authorization for LIVMARLI (maralixibat) oral solution.","Indicated for cholestatic pruritus in Alagille syndrome patients aged 2 months and older.","First and only approved treatment for ALGS in both EU and US; ALGS affects 1 in 30,000 globally.","Approval follows positive CHMP opinion from September 2022.","Authorization covers all 27 EU member states for marketing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339253,"accession_number":"0001193125-22-293893","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2022-11-29T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Mirum discontinues OHANA Phase 2b trial of volixibat in ICP due to enrollment feasibility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Discontinued Phase 2b OHANA trial of volixibat for intrahepatic cholestasis of pregnancy (ICP).","Interim analysis showed meaningful reductions in serum bile acids and pruritus in treated patients.","Decision driven by unique enrollment challenges in high-risk pregnancy setting.","Company will prioritize other pipeline programs following the discontinuation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-11-29T23:59:59+00:00|339253"}